241 related articles for article (PubMed ID: 30209067)
41. The MYB-NFIB gene fusion-a novel genetic link between adenoid cystic carcinoma and dermal cylindroma.
Fehr A; Kovács A; Löning T; Frierson H; van den Oord J; Stenman G
J Pathol; 2011 Jul; 224(3):322-7. PubMed ID: 21618541
[TBL] [Abstract][Full Text] [Related]
42. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.
Yusenko MV; Trentmann A; Andersson MK; Ghani LA; Jakobs A; Arteaga Paz MF; Mikesch JH; Peter von Kries J; Stenman G; Klempnauer KH
Cancer Lett; 2020 Jun; 479():61-70. PubMed ID: 32014461
[TBL] [Abstract][Full Text] [Related]
43. AKT3 drives adenoid cystic carcinoma development in salivary glands.
Zboray K; Mohrherr J; Stiedl P; Pranz K; Wandruszka L; Grabner B; Eferl R; Moriggl R; Stoiber D; Sakamoto K; Wagner KU; Popper H; Casanova E; Moll HP
Cancer Med; 2018 Feb; 7(2):445-453. PubMed ID: 29282901
[TBL] [Abstract][Full Text] [Related]
44. MYB Labeling by Immunohistochemistry Is More Sensitive and Specific for Breast Adenoid Cystic Carcinoma than MYB Labeling by FISH.
Poling JS; Yonescu R; Subhawong AP; Sharma R; Argani P; Ning Y; Cimino-Mathews A
Am J Surg Pathol; 2017 Jul; 41(7):973-979. PubMed ID: 28498281
[TBL] [Abstract][Full Text] [Related]
45. Differences in MYB expression and gene abnormalities further confirm that salivary cribriform basal cell tumors and adenoid cystic carcinoma are two distinct tumor entities.
Tian Z; Li L; Zhang CY; Gu T; Li J
J Oral Pathol Med; 2016 Oct; 45(9):698-703. PubMed ID: 26711587
[TBL] [Abstract][Full Text] [Related]
46. MYB immunostaining is a useful ancillary test for distinguishing adenoid cystic carcinoma from pleomorphic adenoma in fine-needle aspiration biopsy specimens.
Pusztaszeri MP; Sadow PM; Ushiku A; Bordignon P; McKee TA; Faquin WC
Cancer Cytopathol; 2014 Apr; 122(4):257-65. PubMed ID: 24302647
[TBL] [Abstract][Full Text] [Related]
47. Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83.
Ge XY; Yang LQ; Jiang Y; Yang WW; Fu J; Li SL
PLoS One; 2014; 9(6):e101207. PubMed ID: 24963720
[TBL] [Abstract][Full Text] [Related]
48. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
[TBL] [Abstract][Full Text] [Related]
49. MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene.
Kim J; Geyer FC; Martelotto LG; Ng CK; Lim RS; Selenica P; Li A; Pareja F; Fusco N; Edelweiss M; Kumar R; Gularte-Merida R; Forbes AN; Khurana E; Mariani O; Badve S; Vincent-Salomon A; Norton L; Reis-Filho JS; Weigelt B
J Pathol; 2018 Feb; 244(2):143-150. PubMed ID: 29149504
[TBL] [Abstract][Full Text] [Related]
50. Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma.
Ouyang DQ; Liang LZ; Ke ZF; Zheng GS; Weng DS; Yang WF; Su YX; Liao GQ
Head Neck; 2017 Jun; 39(6):1145-1154. PubMed ID: 28230926
[TBL] [Abstract][Full Text] [Related]
51. The value of MYB as a prognostic marker for adenoid cystic carcinoma: Meta-analysis.
Liu X; Chen D; Lao X; Liang Y
Head Neck; 2019 May; 41(5):1517-1524. PubMed ID: 30759319
[TBL] [Abstract][Full Text] [Related]
52. MYB rearrangement and immunohistochemical expression in adenomyoepithelioma of the breast: a comparison with adenoid cystic carcinoma.
Baraban E; Zhang PJ; Jaffer S; Lubin D; Feldman M; Bleiweiss IJ; Nayak A
Histopathology; 2018 Dec; 73(6):897-903. PubMed ID: 30003572
[TBL] [Abstract][Full Text] [Related]
53. A subset of prostatic basal cell carcinomas harbor the MYB rearrangement of adenoid cystic carcinoma.
Bishop JA; Yonescu R; Epstein JI; Westra WH
Hum Pathol; 2015 Aug; 46(8):1204-8. PubMed ID: 26089205
[TBL] [Abstract][Full Text] [Related]
54. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
55. Clinical utility of myb rearrangement detection and p63/p40 immunophenotyping in the diagnosis of adenoid cystic carcinoma of minor salivary glands: a pilot study.
Argyris PP; Wetzel SL; Greipp P; Wehrs RN; Knutson DL; Kloft-Nelson SM; García JJ; Koutlas IG
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Mar; 121(3):282-9. PubMed ID: 26711711
[TBL] [Abstract][Full Text] [Related]
56. The effect of proteoglycans inhibited by RNA interference on metastatic characters of human salivary adenoid cystic carcinoma.
Shi H; Wang J; Dong F; Wang X; Li H; Hou Y
BMC Cancer; 2009 Dec; 9():456. PubMed ID: 20025737
[TBL] [Abstract][Full Text] [Related]
57. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
58. In-depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type.
Bell D; Bell AH; Bondaruk J; Hanna EY; Weber RS
Cancer; 2016 May; 122(10):1513-22. PubMed ID: 26953815
[TBL] [Abstract][Full Text] [Related]
59. High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy.
Liu H; Du L; Wang R; Wei C; Liu B; Zhu L; Liu P; Liu Q; Li J; Lu SL; Xiao J
Oncotarget; 2015 May; 6(13):11477-91. PubMed ID: 25909167
[TBL] [Abstract][Full Text] [Related]
60. Mammalian target of rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual activation of c-Jun NH2-terminal kinase and inhibition of extracellular signal-regulated kinase.
Sun ZJ; Chen G; Zhang W; Hu X; Huang CF; Wang YF; Jia J; Zhao YF
J Pharmacol Exp Ther; 2010 Aug; 334(2):500-12. PubMed ID: 20484154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
